BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Advanced Catheter Therapies Names Scientific Advisory Board


12/18/2012 8:54:10 AM

CHATTANOOGA, TN--(Marketwire - December 18, 2012) -

Advanced Catheter Therapies, Inc. (ACT), (www.acatheter.com) has announced the members of its Scientific Advisory Board, who will advise and assist the company in the development of current and future pipeline products.

"We are incredibly honored to have been able to attract people of this caliber to serve in an advisory capacity," said Paul J. Fitzpatrick, CEO of ACT. "Bringing together these thought leaders will have a profound impact on ACT's ability to develop catheter-based medical devices that improve endovascular procedures. We look forward to their guidance and experience to help accelerate our innovative devices so they can begin to benefit prospective patients as soon as possible."

ACT's lead product is the patented Occlusion Perfusion Catheter™ (OPC), a multi-lumen balloon catheter designed to temporarily occlude a specific region from blood flow to allow the local delivery of therapeutic agents to the peripheral and eventually the coronary vasculature. The OPC has the ability to create a localized treatment chamber for the delivery of various types of therapeutic agents, including pharmaceuticals, live cells and biologics, to treat a variety of disease states and place the agent circumferentially into the vasculature of the treatment chamber.

The members of the ACT Scientific Advisory Board are:

Frank T. Bunch, M.D. FACC, FSCAI - Dr. Bunch is a partner in Cardiology Associates of Mobile, Inc. and has multiple board certifications and hospital affiliations. He is a member of numerous professional societies. He has served as proctor and faculty for many endovascular conferences. Dr. Bunch is currently president of the New Cardiovascular Horizons Group.

Dr. Bunch graduated from Meharry Medical College in 1987 and completed a residency in Internal Medicine at the University of the South Alabama Medical Center in 1992. He was Chief Resident in his senior year. He completed a fellowship in cardiology at Alton Oschner Medical Foundation from 1992-1995. He continued there as a fellow in interventional cardiology from 1995-1996.

In 1992 he received the P.D. McGehee Award for Scientific Writing. He has many publications and presentations and is on the Editorial Advisory Board of Cardiac Interventions Today. He has been a principal investigator for over 20 clinical investigational research studies.

Henry J. Krebs, III, M.D. - Dr. Krebs is a partner of Atlanta Radiology Consultants, P.C. after spending 15 years in academic medicine at Emory University School of Medicine. He has numeral hospital appointments and serves on many hospital committees. His input on design, development and functionality of devices is sought by many of the invasive device manufacturers.

Dr. Krebs graduated Doctor of Medicine from Texas A&M in 1981. He did a residency in diagnostic radiology at the University of Texas-San Antonio from 1981-1985, serving as chief resident in his senior year. He did a fellowship in angiography and interventional radiology from 1985-1986 at Emory University Hospital. He is board certified and a member of multiple medical societies.

Saami Yazdani, Ph.D. - Dr. Yazdani specializes in cardiovascular biomechanics and vascular biology. His research has included a variety of topics from characterization of device-induced mechanical disturbance, in vitro and computational modeling, pre-clinical modeling, cardiovascular pathology, cell therapy and drug delivery.

Dr. Yazdani is currently an Assistant Professor in the Department of Mechanical Engineering at the University of South Alabama. He performed his postdoctoral training at CVPath Institute, evaluating the safety and efficacy of cardiovascular devices using pre-clinical and bench-top models. Dr. Yazdani obtained a Ph.D. in Biomedical Engineering from Wake Forest University, where he developed tissue engineered blood vessels. He has undergraduate and Master's degrees from Virginia Tech in Engineering Science and Mechanics. Dr. Yazdani has published over 80 peer-reviewed journal papers, book chapters and conference abstracts.

C. Rex Teeslink, M.D. - Dr. Teeslink is an inventor and the co-founder of ACT. He is a vascular and interventional radiologist with over 40 years of experience. He received his M.D. degree from Tulane University School of Medicine in New Orleans and completed his radiology residency at the University of Virginia in Charlottesville.

Dr. Teeslink began his practice in 1968 as Chief of Vascular and Interventional Radiology at the Medical College of Georgia, the Veterans Administration and three private hospitals in Augusta, Georgia. He served in this capacity for 30 years, and continues his medical practice through medical consulting companies.

Dr. Teeslink has been actively involved throughout his career in leading-edge technology and continues to assist in the design, development and implementation of numerous medical devices and X-ray equipment. Dr. Teeslink has served as medical director and consultant for several companies. He has been instrumental in helping develop many of the interventional procedures that are utilized today. Dr. Teeslink has always been involved in medical education endeavors, including training medical students, residents, fellows and post graduate physicians. A recognized expert in his field, he has shared his knowledge and experience at numerous medical conferences, both nationally and internationally.

About ACT
Advanced Catheter Therapies, an early stage research and development medical device company, has a portfolio of innovative catheter technologies targeting vascular disease including thrombosis, inflammation, occlusions and restenosis. www.acatheter.com


Media inquiries:
Lynn Hood
Email Contact
678-427-5040

ACT contact:
Paul Fitzpatrick
Email Contact
770-321-8439

Digg this    Bookmark with del.icio.us    Add to Newsvine

Technorati:



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES